



ISCT Clinical Development & Trial Design Strategy (CDT) Committee ESP Leadership Development Program

Clinical Development & Trial Design Strategy Committee Scope:

The ISCT CDT is a new committee to join the ISCT Industry Committee portfolio in 2022. The Committee aims to provide a community for those involved in managing cell and gene therapy clinical trials as a forum to troubleshoot, collaborate and learn from recent advancements in the field. Monthly meetings discuss clinical trial design optimization, therapeutic development strategy (best practices and learnings), patient recruitment, long term registry management and patient advocacy.

Member profile for CDT Committee:

- Chief Medical Officers (CMOs)
- Clinical Research Organizations (CROs)
- Clinicians (MDs)
- Pls of active Clinical Trials
- Patient Advocacy Groups

ESP Member Responsibilities and Opportunities:

The CDT Committee is looking for 1-2 ESPs who are driven, enthusiastic and adaptable to support in executing the Committee's launch and growth.

The ESP will benefit from mentorship from leaders in the cell and gene therapy industry from across the globe and spectrum of companies involved in cell and gene therapy translation including therapeutic developers, pharmaceutical companies and CROs.

The CDT Committee ESP(s) will assist in the executing the Committee's identified initiatives. Support may include, but not limited to:

- **Presentation & Report development**
- **Resource outsourcing**
- **Current Events**

Attendance to monthly Committee is required for success in this position. The ESP will work closely with the Committee Chair and ISCT Head Office Liaison

The term of the CDT Committee ESP Position is 2 years.